Cardiac Biomarkers Testing Market Size, Share, Analysis 2030

Segments - Global Cardiac Biomarkers Testing Market by Types (Creatine Kinase (CK-MB), Troponins, Myoglobins, Natriuretic Peptides [BNP and NT-proBNP], Ischemia Modified Albumins, and Others), Applications (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), and Location of Testing (Point-of-care Testing and Laboratory Testing), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) Forecasts, 2021-2028.

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

The global cardiac biomarkers testing market is anticipated to expand at substantial CAGR of 10.8% during the forecast period, between 2021 and 2028. Cardiac biomarkers are protein particles that are discharged into the blood subsequent to heart stress or heart damage. These biomarker acts as a probable gadget to spot a variety of cardiovascular diseases including myocardial infarction, congestive heart failure, cardiac ischemia, and acute coronary syndrome. The cardiac biomarker tests permit the doctor to determine the danger of a patient related with such diseases.

Global Cardiac Biomarkers Testing Market summary

The biomarkers facilitate the timely recognition of cardiovascular circumstances and assist patients prevent these situations, such as acute coronary syndrome and myocardial infarction. According to World Health Organization (WHO), in the US, approximately 18 million people died from cardiovascular disease. The myocardial infarction is one of the situations that arise due to cardiovascular diseases. This causes major death and morbidity. A timely identification of heart conditions allows doctors to examine the risk of their patients and recommend applicable treatment.

Market Trends, Drivers, Restraints, and Opportunities:

Rising elderly population and increasing number of patients suffering from chest pain and heart attacks owing to change in lifestyles are anticipated to boost the growth of the global market in the coming years.
Increasing financial support from private and public organizations for investigation on cardiac biomarkers is projected to drive the market growth in the upcoming years.
Limited specificity in a few cases and side effects related to cardiac biomarkers such as skeletal muscle wound are likely to hamper the global cardiac biomarkers testing market growth in the coming years.
Ongoing R&D investment for advanced diagnostic tools can create lucrative opportunities during the forecast period.

Scope of the report:

The report on cardiac biomarkers testing market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Attributes	Details
Report Title	Cardiac Biomarkers Testing Market – Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2020
Historic Data	2018 & 2019
Forecast Period	2021–2028
Segmentation	Types (Creatine Kinase (CK-MB), Troponins, Myoglobins, Natriuretic Peptides [BNP and NT-proBNP], Ischemia Modified Albumins, and Others), Applications (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), and Location of Testing (Point-of-care Testing and Laboratory Testing)
Regional Scope	Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
Report Coverage	Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast
Key Players Covered in the Report	Abbott Laboratories, Becton, Dickinson and Company, BioMérieux, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Randox Laboratories, Siemens Healthineers, and Thermo Fisher Scientific

Cardiac Biomarkers Testing Market Segment Insights:

Troponins segment is is projected to hold significant market share

In the terms of types, the market can be divided into creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides; ischemia modified albumins, and others. The natriuretic peptides are further divided into BNP and NT-proBNP. The troponins segment held a major share in 2020 and is expected to continue its domination throughout the forecast period owing to rising occurrence of myocardium infarction and acute coronary syndrome, which increases the number of congestive heart failure cases all over the globe.

Global Cardiac Biomarkers Testing Market types

Myocardial Infarction to hold substantial share in the global market

Based on applications, the cardiac biomarkers testing market can be fragmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. The myocardial infarction segment is projected to hold a significant share in the market owing to rising prevalence of cardiovascular diseases and increased demand for biomarker tests for early detection of heart failure.

Global Cardiac Biomarkers Testing Market applications

Laboratory testing segment to dominate the market

On the basis of location of testing, the cardiac biomarkers testing market can be divided into point-of-care testing and laboratory testing. The laboratory testing segment is anticipated to lead the global market due to the increasing disposable incomes, healthcare expenditure, healthcare infrastructure, and government initiatives for preventing heart attacks

North America expected to grow at a significant rate in the forecasted period

In terms of regions, the cardiac biomarkers testing market can be divided into Asia pacific, North America, Europe, Latin America, and Middle East & Africa. The North America is expected to hold a majority share in the global market owing to high expenses on research and development, presence of key players and their product accessibility, and well recognized healthcare infrastructure in the region.

Global Cardiac Biomarkers Testing Market regions

Segments

By Types

Creatine Kinase (CK-MB)
Troponins
Myoglobins
Natriuretic Peptides
- BNP
- NT-proBNP
Ischemia Modified Albumins
Others

By Applications

Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others

By Location of Testing

Point-of-care Testing
Laboratory Testing

By Regions

Asia Pacific
North America
Europe
Latin America
Middle East & Africa

By Key Players

Abbott Laboratories
Becton
Dickinson and Company
BioMérieux
Bio-Rad Laboratories, Inc.
Danaher Corporation
F. Hoffmann-La Roche AG
Randox Laboratories
Siemens Healthineers
Thermo Fisher Scientific

Competitive Landscape

Key players in the cardiac biomarkers testing market include Abbott Laboratories, Becton, Dickinson and Company, BioMérieux, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Randox Laboratories, Siemens Healthineers, and Thermo Fisher Scientific. These players engage in mergers & acquisitions, collaborations, agreements, and partnerships to strengthen their geographical presence.

Global Cardiac Biomarkers Testing Market keyplayers

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cardiac Biomarkers Testing Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Cardiac Biomarkers Testing Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Cardiac Biomarkers Testing Market - Supply Chain
  4.5. Global Cardiac Biomarkers Testing Market Forecast
     4.5.1. Cardiac Biomarkers Testing Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Cardiac Biomarkers Testing Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Cardiac Biomarkers Testing Market Absolute $ Opportunity
5. Global Cardiac Biomarkers Testing Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Cardiac Biomarkers Testing Market Size and Volume Forecast by Types
     5.3.1. Creatine Kinase (CK-MB)
     5.3.2. Troponins
     5.3.3. Myoglobins
     5.3.4. Natriuretic Peptides
     5.3.5. Ischemia Modified Albumins
     5.3.6. Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Cardiac Biomarkers Testing Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Cardiac Biomarkers Testing Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Cardiac Biomarkers Testing Demand Share Forecast, 2019-2026
7. North America Cardiac Biomarkers Testing Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Cardiac Biomarkers Testing Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Cardiac Biomarkers Testing Market Size and Volume Forecast by Types
     7.4.1. Creatine Kinase (CK-MB)
     7.4.2. Troponins
     7.4.3. Myoglobins
     7.4.4. Natriuretic Peptides
     7.4.5. Ischemia Modified Albumins
     7.4.6. Others
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Cardiac Biomarkers Testing Demand Share Forecast, 2019-2026
8. Latin America Cardiac Biomarkers Testing Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Cardiac Biomarkers Testing Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Cardiac Biomarkers Testing Market Size and Volume Forecast by Types
     8.4.1. Creatine Kinase (CK-MB)
     8.4.2. Troponins
     8.4.3. Myoglobins
     8.4.4. Natriuretic Peptides
     8.4.5. Ischemia Modified Albumins
     8.4.6. Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Cardiac Biomarkers Testing Demand Share Forecast, 2019-2026
9. Europe Cardiac Biomarkers Testing Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Cardiac Biomarkers Testing Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Cardiac Biomarkers Testing Market Size and Volume Forecast by Types
     9.4.1. Creatine Kinase (CK-MB)
     9.4.2. Troponins
     9.4.3. Myoglobins
     9.4.4. Natriuretic Peptides
     9.4.5. Ischemia Modified Albumins
     9.4.6. Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Cardiac Biomarkers Testing Demand Share Forecast, 2019-2026
10. Asia Pacific Cardiac Biomarkers Testing Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Cardiac Biomarkers Testing Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Cardiac Biomarkers Testing Market Size and Volume Forecast by Types
     10.4.1. Creatine Kinase (CK-MB)
     10.4.2. Troponins
     10.4.3. Myoglobins
     10.4.4. Natriuretic Peptides
     10.4.5. Ischemia Modified Albumins
     10.4.6. Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Cardiac Biomarkers Testing Demand Share Forecast, 2019-2026
11. Middle East & Africa Cardiac Biomarkers Testing Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Cardiac Biomarkers Testing Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Cardiac Biomarkers Testing Market Size and Volume Forecast by Types
     11.4.1. Creatine Kinase (CK-MB)
     11.4.2. Troponins
     11.4.3. Myoglobins
     11.4.4. Natriuretic Peptides
     11.4.5. Ischemia Modified Albumins
     11.4.6. Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Cardiac Biomarkers Testing Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Cardiac Biomarkers Testing Market: Market Share Analysis
  12.2. Cardiac Biomarkers Testing Distributors and Customers
  12.3. Cardiac Biomarkers Testing Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Abbott Laboratories
     12.4.2. Becton
     12.4.3. Dickinson and Company
     12.4.4. BioMérieux
     12.4.5. Bio-Rad Laboratories, Inc.
     12.4.6. Danaher Corporation
     12.4.7. F. Hoffmann-La Roche AG
     12.4.8.